Department of Nutrition, Food Hygiene and Toxicology, West China School of Public Health and Healthy Food Evaluation Research Center, Sichuan University, 610041, Chengdu, Sichuan, PR China.
Department of Pediatrics of Western China Second Hospital of Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children, 610041, Chengdu, Sichuan, PR China.
Sci Rep. 2019 Mar 1;9(1):3254. doi: 10.1038/s41598-018-35737-1.
Recent studies have demonstrated that antibiotics/or probiotics administration in early life play key roles on modulating intestinal microbiota and the alterations might cause long-lasting consequences both physiologically and immunologically. We investigated the effects of early life ceftriaxone, vancomycin and Bifidobacterium bifidum TMC3115 (TMC3115) treatment on intestinal microbiota and immunity both in neonates and adults even after termination of antibiotics exposure. We found that ceftriaxone and vancomycin, but not TMC3115, significantly altered the intestinal microbiota, serum total IgE level, and the morphology and function of the intestinal epithelium in the neonatal mice. In the adult stages, the diversity and composition of the intestinal microbiota were significantly different in the antibiotic-treated mice, and ceftriaxone-treated mice exhibited significantly higher serum total IgE and OVA-specific IgE levels. TMC3115 significantly mitigated the alteration of intestinal microbiota caused by ceftriaxone not vancomycin. Antibiotics and TMC3115 can differently modulate intestinal microbiota and SCFAs metabolism, affecting the development and function of the immunity and intestinal epithelium to different degrees in neonatal mice. Neonatal ceftriaxone-induced abnormal intestinal microbiota, immunity and epithelium could last to adulthood partly, which might be associated with the enhancement of host susceptibility to IgE-mediated allergies and related immune responses, TMC3115 may protect against the side effects of antibiotic treatment, at least partly.
最近的研究表明，抗生素/益生菌在生命早期的使用对调节肠道微生物群起着关键作用，这些变化可能会在生理和免疫上产生持久的影响。我们研究了早期生活中头孢曲松、万古霉素和双歧杆菌 TMC3115（TMC3115）治疗对肠道微生物群和免疫的影响，即使在停止抗生素暴露后也是如此。我们发现，头孢曲松和万古霉素，但不是 TMC3115，显著改变了新生小鼠的肠道微生物群、血清总 IgE 水平以及肠道上皮的形态和功能。在成年阶段，抗生素处理的小鼠肠道微生物群的多样性和组成有显著差异，头孢曲松处理的小鼠血清总 IgE 和 OVA 特异性 IgE 水平显著升高。TMC3115 显著减轻了头孢曲松引起的肠道微生物群的改变，但对万古霉素没有影响。抗生素和 TMC3115 可以不同地调节肠道微生物群和 SCFAs 代谢，在新生小鼠中对免疫和肠道上皮的发育和功能产生不同程度的影响。新生头孢曲松诱导的异常肠道微生物群、免疫和上皮可能会持续到成年期，这可能与宿主对 IgE 介导的过敏和相关免疫反应的易感性增强有关，TMC3115 可能至少部分地预防抗生素治疗的副作用。
